Driven by Biopharmaceutical Innovations and Gene Therapies, the market Booms Amidst Growing Incidence of Hemophilia and Von Willebrand Disease ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Then on Jan. 6, affiliated company WuXi Biologics said its subsidiary WuXi Vaccines plans to sell its vaccine plant in ...

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Telix enters into asset purchase agreement with antibody engineering company ImaginAb The deal adds a ...

Meanwhile, WuXi Vaccines, a subsidiary of WuXi Biologics, says it will sell a vaccine facility in Dundalk, Ireland, to the US drugmaker Merck & Co. for $521 million. WuXi Biologics says the sale ...

Dr. Michael Har-Noy, Founder and Chief Medical Officer of Mirror Biologics stated: “We are pleased to enter into this clinical collaboration with Merck KGaA, Darmstadt, Germany, evaluating the ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

China's WuXi Biologics has announced plans to sell its vaccine facility in Ireland to U.S. pharmaceutical giant Merck & Co. for approximately USD 500 million. The decision comes ahead of potential U.S ...